Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback